Literature DB >> 3383994

Pharmacokinetics and safety of l-carnitine infused i.v. in healthy subjects.

T Uematsu1, T Itaya, M Nishimoto, Y Takiguchi, A Mizuno, M Nakashima, K Yoshinobu, T Hasebe.   

Abstract

The pharmacokinetics and safety of a brief i.v. infusion of l-carnitine 0, 20, 40 and 60 mg/kg have been investigated in 10 healthy subjects. The diurnal intraindividual variability of plasma carnitine was small (C. V. = 3.0, 3.9 and 3.9%, respectively), and the total 24 h excretion in urine was also small and relatively constant: 4.6, 21.5 and 13.0 mg/day in the controls vs 4.6, 20.2 and 6.0 mg/day during treatment in the three subjects to whom saline alone was administered according to a single-blind design. Therefore, the pre-dose level of carnitine was subtracted from the level after dosing for the pharmacokinetic analysis. Plasma carnitine fitted well to a three-compartment open model, with Vc of 0.11-0.20 l/kg and a t1/2 gamma of 10-23 h. The urine recovery in 24 h was 77.2-95.4%. There were no objective or subjective side-effects attributable to carnitine, so its i.v. infusion is considered to be safe.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383994     DOI: 10.1007/bf00614562

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  ENZYMOLOGICAL DETERMINATION OF FREE CARNITINE CONCENTRATIONS IN RAT TISSUES.

Authors:  N R MARQUIS; I B FRITZ
Journal:  J Lipid Res       Date:  1964-04       Impact factor: 5.922

2.  CARNITINE ACETYLTRANSFERASE. II. INHIBIITON BY CARNITINE ANALOGUES AND BY SULFHYDRYL REAGENTS.

Authors:  I B FRITZ; S K SCHULTZ
Journal:  J Biol Chem       Date:  1965-05       Impact factor: 5.157

3.  Action of carnitine on long chain fatty acid oxidation by liver.

Authors:  I B FRITZ
Journal:  Am J Physiol       Date:  1959-08

4.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

5.  Protection of the ischemic dog myocardium with carnitine.

Authors:  J D Folts; A L Shug; J R Koke; N Bittar
Journal:  Am J Cardiol       Date:  1978-06       Impact factor: 2.778

6.  Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia.

Authors:  A L Shug; J H Thomsen; J D Folts; N Bittar; M I Klein; J R Koke; P J Huth
Journal:  Arch Biochem Biophys       Date:  1978-04-15       Impact factor: 4.013

7.  Improved pacing tolerance of the ischemic human myocardium after administration of carnitine.

Authors:  J H Thomsen; A L Shug; V U Yap; A K Patel; T J Karras; S L DeFelice
Journal:  Am J Cardiol       Date:  1979-02       Impact factor: 2.778

8.  Pharmacokinetics of l-carnitine in man following intravenous infusion of dl-carnitine.

Authors:  P G Welling; J H Thomsen; A L Shug; F L Tse
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-02

9.  Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport.

Authors:  L J Waber; D Valle; C Neill; S DiMauro; A Shug
Journal:  J Pediatr       Date:  1982-11       Impact factor: 4.406

  9 in total
  6 in total

1.  Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers.

Authors:  A Marzo; E Arrigoni Martelli; R Urso; M Rocchetti; V Rizza; J G Kelly
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

3.  Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.

Authors:  S Pace; A Longo; S Toon; P Rolan; A M Evans
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

4.  A pharmacokinetic model for L-carnitine in patients receiving haemodialysis.

Authors:  Gianfranco Fornasini; Richard N Upton; Allan M Evans
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

Review 5.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  The molecular structure of β-alanine is resistant to sterilising doses of gamma radiation.

Authors:  Lívia de Souza Gonçalves; Mariana Franchi; Monica B Mathor; Ademar B Lugao; Victor H Carvalho; Marisa H G Medeiros; Guilherme Giannini Artioli; Gustavo H C Varca
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.